Virtu Financial’s BridgeBio Pharma BBIO Stock Holding History

Virtu Financial’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,073	Closed	-$245K	–	1412
2023 Q4	$245K	Buy	+6,073	New	+$182K	0.02%	704
2022 Q1	–	Sell	-107,707	Closed	-$1.8M	–	1496
2021 Q4	$1.8M	Buy	+107,707	New	+$4.56M	0.18%	112
2021 Q1	–	Sell	-5,622	Closed	-$400K	–	1595
2020 Q4	$400K	Sell	5,622 -666	-11%	-$32.1K	0.04%	518
2020 Q3	$236K	Buy	+6,288	New	+$198K	0.04%	525
2019 Q4	$230K	Buy	+6,557	New	+$182K	0.02%	831

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Virtu Financial's BBIO Position: Q1 2024 in Review

Virtu Financial sold out of BridgeBio Pharma (BBIO) in Q1 2024, closing a stake of 6,073 shares — an estimated $245K sold.

Virtu Financial first reported a position in BBIO in Q4 2019 and held it in 5 quarters. The position peaked at $1.8M in Q4 2021. 244 funds tracked by Wall St. Rank hold BBIO as of Q1 2024.

Virtu Financial reported no remaining BridgeBio Pharma position as of Q1 2024 after selling out during the quarter.
Virtu Financial sold 6,073 BridgeBio Pharma shares in Q1 2024, an estimated $245K.
Virtu Financial first reported a position in BridgeBio Pharma in Q4 2019 and held it in 5 quarters.
Virtu Financial's BridgeBio Pharma position peaked at $1.8M in Q4 2021.
244 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2024.

Based on Virtu Financial's 13F filing for Q1 2024, filed 20 May 2024.